Preview

Rational Pharmacotherapy in Cardiology

Advanced search

SUPRAVENTRICULAR RHYTHM DISTURBANCES TREATMENT WITH ANTIARHYTHMIC DRUG III CLASS NIBENTAN IN PATIENTS WITH ISCHEMIC HEART DISEASE (EXPERIMENTAL, CLINICAL AND MORPHOLOGICAL EVIDENCES)

https://doi.org/10.20996/1819-6446-2006-2-1-41-47

Full Text:

Abstract

Aim. To evaluate antiarhythmic efficiency of Nibentan (Verofarm, Russia), antiarrythmic drug III class, in supraventricular rhythm disturbances (SRD) relief in patients with ischemic heart disease (IHD). To assess morphological changes of myocardium in IHD with SRD. To specify inotropic characteristics of nibentan in experiment. Material and methods. 55 patients with IHD with different SRD were studied. 41 patients had heart failure (HF) of III functional class.14 other patients suffered acute myocardial infarction (AMI). SRD relief was achieved with 1% solution of nibentan in dose of 0.125 mg/kg patient's weight. After sinus rhythm recovery all patients received sotalol 80 mg twice a day to prevent SRD relapses. In vitro on myocardium of 10 healthy rats and 10 sliced myocardium strips of IHD patients (obtained during surgical intervention) changes in myocardium contraction intensity were assessed with PowerLab plant (ADInstruments, Australia) as a reaction on nibentan in doses of 4, 6 and 8 mkM. These doses correspond to doses of 0.125, 0.2 and 0.250 mg/kg, which are recommended for clinical practice. Histological study of autopsy materials of atrium myocardium of IHD patients with and without SRD was carried out. Phase-contrast and luminescent microscopy was also used. Results. Nibentan treatment lead to sinus rhythm recovery in 92.67% of HF patients. In 3 patients with persistent auricular fibrillation the drug was inefficient. Nibentan therapy did not result in blood pressure reduction. Heart rate decreased in 26.5%. Nibentan recovered sinus rhythm in 85.7% of AMI patients. Sinus rhythm didn't recover in 2 patients with persistent auricular fibrillation. Experimental studies revealed that myocardium contraction intensity in healthy rats increased at nibentan 4 and 6 mkM, and decreased at nibentan 8 mkM. Myocardium contraction intensity in IHD patients was decreasing while nibentan dose was growing. Histological study of auricular myocardium in IHD patients with SRD compared to myocardium in IHD patients without SRD, showed predominance of the following characteristics: fibrolipomatosis, focal and diffusive fibrosis and sclerosis, chaotic allocation of cardiac cells, muscular-elastic hyperplasia of vascular intima, contractile degeneration (at phase-contrast microscopy). Conclusion. Nibentan in bolus i.v. administration in dose of 0.125 mg/kg is effective drug for SRD relief in patients with IHD with HF and in patients with AMI. It doesn't affect BP significantly. According to data of experiments dose of nibentan 0.125mg/kg is optimal for inotropic function of myocardium. More significant histological changes in auricular myocardium can be the reason of SRD.

About the Authors

I. A. Latfullin
Kazan State Medical University
Russian Federation
Department of internal medicine N 2


R. F. Gaifullina
Kazan State Medical University
Russian Federation
Department of internal medicine N 2


References

1. Арлеевский И. П. Электроимпульсная терапия нарушений сердечного ритма: методические рекомендации / И. П. Арлеевский, Э. Ф. Пичугина, Э. В Пак. – Казань, 1985. – 30 с.

2. Кушаковский М. С. Аритмия сердца: рук-во для врачей / М. С. Кушаковский // Санкт-Петербург. – 1999. – С. 498-504.

3. Преображенский Д. В. Фибрилляция предсердий: выбор фармакологической кардиоверсии / Д. В. Преображенский [и др.] // Кардиология. – 2005. – № 4. – С. 72-80.

4. Розенштраух Л. В. Электрофизиологические аспекты кардиотропного действия нового антиаритмического препарата нибентана (экспериментальные исследования) / Л. В. Розенштраух, Е. П. Анюховский, Г. Г. Белошапко [и др.] // Кардиология. – 1995. – № 35(5). – С. 25-36.

5. Розенштраух Л. В. Нибентан – первый оригинальный отечественный аниаримический препарат III класса. Электрофизиологические эффекты и механизмы антиаритмического действия нибентана у больных с пароксизмальными тахиаритмиями / Л. В. Розенштраух, С. П. Голицин // Актовые лекции. – М., 2002. – 34 с.

6. Руда М.Я. Клиническое изучение нового антиаритмического препарата III класса - нибентана. Сообщение 1. Исследование переносимости / М. Я. Руда, И. Н. Меркулова, А. Э. Тарарак // Кардиология. – 1995. – № 9. – С. 4-15

7. Спасов А. А. Кардиотоксические свойства кордарона в условиях острой ишемии и инфаркта миокарда / А. А. Спасов, Н. А. Гурова // Экспериментальная и клиническая фармакология. – 1997. – № 2. – С. 20-23.

8. Сыркин А. Л. 30 лет электроимпульсной терапии / А. Л. Сыркин, А. В. Недоступ, И. В. Маевская // Терапевтический архив. – 1992. – № 1. – С. 139-142.

9. Татарский Б. А. Протекторный эффект пропафенона при пароксизмальных реципроктных атриовентрикулярных тахикардиях / Татарский Б. А. // Российский кардиологический журнал. – 2004. – № 1(45). – С. 28-32.

10. Федоров В. В. Механизм антиаритмического действия нибентана на экспериментальной модели ваготонической фибрилляции предсердий у собак / В. В. Федоров, О. Ф. Шарифов, Л. В. Розенштраух // Кардиология. – 1999. – № 3. – С. 45-56.

11. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation // Am. Coll.Cardiol. – 2001. – № 38,4. – Р. 1266- 1266.

12. Allessie M. A. Pathophysiology and Prevention of atrial fibrillation / M. A. Allessie, P. A. Boyden, J. Camm // Circulation. – 2001. – N 103. – Р. 769-777.

13. Golitsyn S. Electrophysiologic and antiarrhythmic effects of nibentan a new class III agent in patients with paroxysmal tachyarrhythmias / S. Golitsyn, I. Krutanov, M. Ruda // Eur.Heart J. – 1996. – N 17. (Sappl. Abstr.) – P. 389.

14. Spach M. S. Influence of the passive anisotropic properties directional differences ipropa gation following modification of the sodium conductance in human atria muscle: A model of reentry based on anisotropic discontinues propagation / M. S. Spach, P. C. Dolber, J. F. Heidlage // Circ. Res. – 1988. – Vol. 62. – P.811-832.

15. Spach M. S. Microfibrosis produces electrical load variations due to loss side-tо side cell connections:a major mechanism of structural heart disease arrhythmias / M. S. Spach, J. P. Boineau // PACE. – 1997. – Vol. 20. – P. 397-413.


For citation:


Latfullin I.A., Gaifullina R.F. SUPRAVENTRICULAR RHYTHM DISTURBANCES TREATMENT WITH ANTIARHYTHMIC DRUG III CLASS NIBENTAN IN PATIENTS WITH ISCHEMIC HEART DISEASE (EXPERIMENTAL, CLINICAL AND MORPHOLOGICAL EVIDENCES). Rational Pharmacotherapy in Cardiology. 2006;2(1):41-47. (In Russ.) https://doi.org/10.20996/1819-6446-2006-2-1-41-47

Views: 332


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)